BiotechTube

Seroquel XR

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Alcoholism

Conditions

Alcoholism, Anxiety Disorders, Generalized Anxiety Disorder, Post-Traumatic Stress Disorder, Panic Disorder, Obsessive-Compulsive Disorder

Trial Timeline

Feb 1, 2006 → Nov 1, 2008

NCT ID
NCT00352469

About Seroquel XR

Seroquel XR is a approved stage product being developed by AstraZeneca for Alcoholism. The current trial status is completed. This product is registered under clinical trial identifier NCT00352469. Target conditions include Alcoholism, Anxiety Disorders, Generalized Anxiety Disorder.

What happened to similar drugs?

3 of 8 similar drugs in Alcoholism were approved

Approved (3) Terminated (1) Active (4)
✅Acamprosate or NaltrexoneMerckApproved
✅Acamprosate + PlaceboMerckApproved
✅LevetiracetamUCBApproved
🔄Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
❌Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mgAlkermesPhase 3
🔄Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mgAlkermesPhase 3
🔄Medisorb naltrexone 380 mg + Oral naltrexone 50 mgAlkermesPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01971203Pre-clinicalCompleted
NCT00352469ApprovedCompleted

Competing Products

18 competing products in Alcoholism

See all competitors
ProductCompanyStageHype Score
acamprosateJohnson & JohnsonPre-clinical
26
Topiramate and NaltrexoneJohnson & JohnsonPhase 1
29
TopiramateJohnson & JohnsonPhase 2
35
ondansetron + cognitive behavioral therapy + topiramate + cognitive behavioral therapy + Placebo + cognitive behavioral therapy + ondansetron + topiramate + cognitive behavioral therapyJohnson & JohnsonPhase 2
31
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3
40
topiramateJohnson & JohnsonPhase 2
35
Quetiapine fumarateAstraZenecaPhase 2
35
Acamprosate or NaltrexoneMerckApproved
43
Acamprosate + PlaceboMerckApproved
43
SCH 900435 + PlaceboMerckPhase 2
27
CP-866,087PfizerPhase 2
35
LevetiracetamUCBApproved
43
levetiracetamUCBPhase 2
35
Nalmefene + PlaceboLundbeckPhase 1
18
Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mgAlkermesPhase 3
29
Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mgAlkermesPhase 3
37
Medisorb naltrexone 380 mg + Oral naltrexone 50 mgAlkermesPhase 3
37
Medisorb naltrexone 190 mg + Medisorb naltrexone 380 mg + Placebo matching Medisorb naltrexone 190 mg + Placebo matching Medisorb naltrexone 380 mgAlkermesPhase 3
37